1. Medtech Insight

EU Public-Private Partnership Invests €66.8M To ‘Transform Clinical Studies’ By Boosting Diversity

 
• By Anabel Costa-Ferreira

A six-year project aiming to establish a “less fragmented and more democratic” approach to clinical studies has commenced in the EU.

Yellow figurines representing diversity
(Andrey_Popov/Shutterstock)
Key Takeaways
  • A pioneering private-public project launched in the EU aims to improve diversity in clinical research by creating an inclusive ecosystem for clinical trials, focusing on underserved and underrepresented communities
  • The Research in Europe and Diversity Inclusion (REaDI) was launched under the Horizon Europe Innovative Health Initiative (IHI), public-private partnership between the EU and the European life science industries
  • The project is supported by a consortium of 73 organizations and has a budget of €66.8m, with contributions from both the IHI and industry partners
  • REaDI will map community characteristics, develop tools and training programs, test approaches in real-world use cases, and design a patient-centered digital platform

EU public-private stakeholders have joined hands on an ambitious project to improve diversity in clinical research and create “an inclusive European clinical trials ecosystem that values every individual’s health journey.”

Project REaDI (Research in Europe and Diversity Inclusion) was launched on 11 January under the aegis of the Horizon Europe Innovative Health Initiative (IHI) , a public-private partnership between the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

More from Business

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.